A Veterans Administration Cooperative Study investigating chemotherapy after prostatectomy for high-risk prostate cancer was underpowered to show a statistically significant benefit of early adjuvant chemotherapy versus observation as the standard of care in the primary endpoint analysis of progression-free survival.
In this interview, AUA President Richard K. Babayan, MD, discusses his goal to increase member participation in the AUA, the association’s efforts to balance three main priorities, and how the AUA will work with other organizations.
“Patients are definitely running into problems affording these medications,” one urologist told us.
As she nears the end of her residency, Amy Pearlman, MD, reflects on what stressful moments from her time in urology have taught her.
Other kidney cancer research included an 8-gene panel that was able to predict high tumor grade in biopsy specimens and a review of perioperative transfusion’s effect on recurrence-free and overall survival.
Four-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
More than one-fourth of the U.S. urologist work force plans to retire in next 5 years, according to a new study looking at the near-term impact of retirement on the specialty.
FDA approval of second-line therapies could mean an “embarrassment of riches” in this field, according to one expert.
Other key stone disease/endourology topics from the 2016 AUA annual meeting included the use of aspirin in percutaneous nephrolithotomy patients as well as the continuing debate over the benefit of medical expulsive therapy.
Analyses of the urinary and gut microbiomes and a quality improvement to standardize use of antibiotics after prostate biopsy were among other AUA 2016 highlights in this therapeutic area.
The AUA annual meeting provided learning experiences for Henry Rosevear, MD, on multiple levels. Here are eight observations he brought home from San Diego.
Microdissection testicular sperm extraction retrieval rates, adolescent varicocele repair, and evaluation of testosterone replacement therapy and prostate cancer are additional noteworthy topics in this field.
Fusion biopsy, salvage versus adjuvant radiation therapy, and superextended versus extended pelvic lymph node dissection are also covered in the take home messages on prostate cancer from the 2016 AUA annual meeting.
Urologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.
This video demonstrates UroLift placement under topical anesthesia in the office setting and also includes comments from several patients who underwent the procedure.
This video provides an overview of the prostatic urethral lift (UroLift), highlighting the entire cycle of patient care.
Although there is no clear-cut solution to the problem of recurrent UTIs in postmenopausal women, "various strategies can be employed that have found success," write Wade Bushman, MD, PhD, and Brian V. Le, MD, MA.
Urologists and other physicians who serve Medicare patients face some new decisions now that the Centers for Medicare & Medicaid Services has proposed new regulations implementing last year’s fee schedule reform law, while also replacing the existing meaningful use program with a more flexible approach to technology and electronic health records.
One of the greatest benefits of being covered under a high-deductible health plan is generally the ability to open a health savings account and receive tax-preferred treatment on money saved for medical expenses.
“Few physicians are familiar with apology law and even fewer understand the significance,” said Patrick McKenna, MD, chief of the division of pediatric urology at American Family Children’s Hospital and professor of urology at the University of Wisconsin, Madison.
Read about this and two other cases in this "Malpractice Consult" column.
Expression of androgen receptor splice variant 7 (AR-V7) in whole blood predicts worse cancer-related outcomes in patients with metastatic castration-resistant prostate cancer who are treated with abiraterone acetate (ZYTIGA).
"What the AUA can do for those of us in the trenches, so to speak, is to lessen some of the regulatory burdens that have been put on us," says one urologist.
In a series of articles this year, Robert A. Dowling, MD, will examine what you need to know about the law, what the CMS proposed rule for implementation implies for the near and long-term future, and-when it is issued later this year-what the final rule means to your urology practice.
"With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD.